Article
Efficacy of human rotavirus vaccine against severe gastroenteritis in Malawian children in the first two years of life: a randomized, double-blind, placebo controlled trial.
Vaccine - 27 Apr 2012
Cunliffe Nigel A, Witte Desiree, Ngwira Bagrey M, Todd Stacy, Bostock Nancy J, Turner Ann M, Chimpeni Philips, Victor John C, Steele A Duncan, Bouckenooghe Alain, Neuzil Kathleen M
Abstract excerpt
Rotavirus gastroenteritis is a major cause of morbidity and mortality among African infants and young children. A phase III, placebo-controlled, multi-centre clinical trial of a live, oral G1P[8] human rotavirus vaccine (RIX4414) undertaken in Malawi and South Africa significantly reduced the incidence of severe rotavirus gastroenteritis in the first year of life. We now report on vaccine efficacy in the Malawi...
Topics
Join the communities discussing this publication.